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Abstract: NUT midline carcinoma (NMC) is a poorly differentiated 
tumor typically driven by a t(15;19) rearrangement leading to a NUT 
fusion event. This rare and uniformly fatal tumor arises in multiple 
organ sites; however the clinical, radiographic, and pathologic charac-
teristics of primary pulmonary NMC are poorly defined. We identified 
eight cases of primary pulmonary NMC in our consult practice over 4 
years and, using a NUT immunohistochemistry screen, retrospectively 
identified one additional case from 166 (0.6%) consecutive in-house 
biopsies of lung carcinomas lacking glandular differentiation. Eight 
cases had available clinical and radiographic data and shared a remark-
able degree of similarity. The median age at presentation was 30 (range 
21–68). Six patients had little or no smoking history. All complained 
of 1 to 3 months of cough at presentation. Computed tomography 
scans showed a large, centrally located primary mass with confluent 
involvement of mediastinal lymph nodes, pleural disease, and spar-
ing of the contralateral lung. Lytic bone metastases were common 
but brain metastases were absent in all cases. Pathologically, all cases 
showed primitive-appearing round to epitheloid cells growing in nests 
and sheets. All tumors expressed keratin, p63 or p40, and NUT protein. 
Eight cases had a fluorescence in situ hybridization-proven BRD4-NUT 
or BRD3-NUT rearrangement; one case was presumed to have a NUT-
variant fusion event. Median overall survival was 2.2 months. Despite 
the rarity of primary pulmonary NMC, it is important to recognize this 
entity to counsel patients regarding outcome and to identify candidates 
for targeted BRD inhibitors currently in clinical trials.
Key Words: NUT midline carcinoma, Pulmonary, Squamous cell 
carcinoma.
(J Thorac Oncol. 2015;10: 951–959)
NUT midline carcinoma (NMC) is a highly aggressive tumor defined by a rearrangement involving the NUTM1 
(Nut midline carcinoma, family member 1, NUT) gene on 
chromosome 15 and sharing some histopathologic features 
with squamous cell carcinomas. This rearrangement leads to 
the fusion of NUT to one of a number of possible partners 
including the bromodomain family members BRD3 or BRD4 
or the methyltransferase, NSD3, leading to global epigenetic 
reprogramming and loss of cell differentiation.1–5 The tumor 
has been reported to arise in many sites, although the largest 
series suggest a predilection for the head and neck and medi-
astinum.6,7 NMC is extremely aggressive, with most cases pre-
senting at an advanced stage and progressing rapidly to death. 
The estimated 2-year progression-free survival is 9%, based 
on studies incorporating all sites of disease.8
Large series describing NMC in the lung are lacking, 
but existing literature suggests that primary pulmonary NMC 
is exceptionally rare. Tanaka et al.9 described only two cases 
of probable lung origin in a survey of 41 years of cases gath-
ered from their institution, both in pediatric patients. Haruki 
et al.10 derived the cell line HCC2429 from a metastatic lung 
carcinoma proven to contain the t(15;19) translocation, but 
were unable to identify any additional cases of NMC from a 
series of 128 lung carcinomas screened by fluorescence in situ 
hybridization (FISH) for this translocation.
Pathologically, NMC is characterized by often 
monomorphic, primitive-appearing tumor cells frequently 
lacking the protein expression profiles characteristic of 
common carcinomas; however, cases can show squamous 
differentiation in the form of focal, abrupt keratinization 
and/or expression of high molecular weight cytokeratins 
and lineage-specific transcription factors, such as p63 and 
p40 (ΔNp63).7,11 The undifferentiated nature of NMC leads 
to difficulty in morphologic recognition, and thus the dif-
ferential diagnosis is broad, including poorly differenti-
ated non–small-cell carcinoma, small-cell lung carcinoma, 
round cell sarcomas, and high grade lymphomas. An immu-
nohistochemical antibody that specifically detects NUT 
protein overexpression can now facilitate rapid and cost–
effective diagnosis of this rare tumor.12 Experimental stud-
ies suggest that bromodomain inhibitors can drive terminal 
differentiation of NMC cells in culture and are thus a prom-
ising starting point for targeted inhibition of the BRD-NUT 
oncogenes.13
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Although rare, NMC is likely seen at a higher frequency 
at referral cancer centers, due to potentially ambiguous diag-
nostic features and unusually aggressive clinical course. We 
retrospectively examined our consult files for cases diagnosed 
as primary pulmonary NMC and herein describe the clinical, 
radiographic, and pathologic features of eight cases identified 
between 2010 and 2014. In an effort to better understand the 
frequency of the NMC diagnosis in a more routine setting, we 
retrospectively screened in-house biopsies performed for lung 
cancer within our institution between 2002 and 2010, a period 
before screening of poorly differentiated carcinomas for NUT 
overexpression by immunohistochemistry (IHC) became 
commonplace in our practice. As a result of these efforts, we 
demonstrate that primary pulmonary NMC, while rare, has 
highly characteristic symptomatic and radiographic features, 
pathology, and clinical course.
MATERIALS AND METHODS
Case Series
Following approval by the Brigham and Women’s 
Hospital (BWH) Institutional Review Board (IRB), the pathol-
ogy records of BWH were searched for the diagnosis “NMC” 
associated with a biopsy or surgical resection obtained from 
the thoracic cavity. Tumors thought to arise at extrapulmonary 
sites (these included head and neck, kidney, and anterior medi-
astinum) were excluded from review. A total of eight cases 
were identified; all initially presented at an outside hospital 
and were reviewed in consultation at DFCI/BWH between 
2010 and 2014. Pathology slides for all cases with material 
still available in the BWH archives were re-reviewed. Details 
of patient history and clinical course were derived from the 
electronic medical record.
Radiology Methods
The imaging studies at the time of diagnosis were 
reviewed by a board-certified radiologist with expertise in tho-
racic and oncologic imaging (M.N.). All but one patient had 
chest computed tomography (CT) scans available. Additional 
imaging studies, including 18F fluorodeoxyglucose (FDG) 
positron emission tomography (PET)/CT, abdominal CT, head 
CT, bone scintigraphy, and brain magnetic resonance imaging 
(MRI), along with their radiology reports if available, were 
also reviewed if performed. Chest CT scans were evaluated 
focusing on the location and characteristics of the dominant 
lung lesion and associated lung parenchymal abnormalities, 
involvement of the contralateral lung, lymphadenopathy, pleu-
ral, and osseous abnormalities. PET/CT and other imaging 
studies were reviewed to identify the involvement of extra-
thoracic sites.
Screening Cohort
The patient records at Dana Farber Cancer Institute 
(DFCI) were searched for all thoracic oncology patients with a 
biopsy performed for lung cancer at BWH between 2002 and 
2010. The following diagnoses were included: poorly differ-
entiated carcinoma, non–small-cell lung carcinoma (NSCLC), 
squamous cell carcinoma, and high grade neuroendocrine 
carcinoma and/or small cell lung carcinoma. Study cases were 
further restricted to those with adequate formalin-fixed par-
affin-embedded (FFPE) tissue remaining in the archive. All 
specimens included in this study were obtained from patients 
who consented to correlative studies (DFCI IRB 02-180). 
Patient’s demographic and clinical features were derived from 
the medical record.
Immunohistochemistry
IHC for NUT was performed on 4 μm thick FFPE sec-
tions. Slides underwent heat-induced epitope retrieval in citrate 
buffer and were incubated with primary rabbit monoclonal 
anti-NUT (clone C5261, 1:50; Cell Signaling Technology, 
Danvers, MA) and visualized using Bond Polymer Refine 
Detection (Leica Microsystems, Buffalo Grove, IL). IHC 
staining for NUT was interpreted by two or more pathologists 
(S.P., L.M.S., and C.A.F.). Positivity was defined as strong, 
speckled nuclear staining in greater than 50% of nuclei, as 
previously described.12 Additional IHC staining for tumor 
markers was performed at the time of primary diagnosis 
according to standard clinical operating procedures in the 
BWH IHC laboratory. All tumors originally diagnosed as 
NSCLC were stained for this study with thyroid transcription 
factor-1 (TTF-1; M3575, 1:300; DAKO, Carpinteria, CA) and 
p40 (PC373; 1:800; EMD Millipore, Billerica, MA). For both 
stains, antigen retrieval was carried out with citrate buffer in 
a pressure cooker.
Fluorescence In Situ Hybridization
Chromosomal translocation of the NUT gene locus was 
performed by FISH in NUT-IHC positive cases as previously 
described.14 Dual-color split-apart FISH assays were carried 
out on 4-μm-thick FFPE tissue sections. BRD4 on 19p13.1 
was probed using telomeric tandem bacterial artificial chro-
mosome (BAC) clones RP11-319o10 and RP11-681d10 
(green) and centromeric BAC clones RP11-207i16 and CTD-
3055m5 (red). NUT on 15q13 was probed using telomeric 
BAC clones 1H8 and 64o3B (green) and centromeric clones 
1084a12 and 3d4 (red). Split apart of NUT and BRD4 was 
deemed consistent with BRD4-NUT fusion. Dual-color bring-
together FISH assays were carried out for detection of BRD3-
NUT fusion on FFPE tissue sections. BRD3 on 9q34.2 was 
probed using telomeric tandem BAC clones RP11-145e17 and 
RP11-92b21 (red) and NUT was probed using telomeric BAC 
clones as above. Slides with greater than 80% hybridization 
efficiency in four areas (200 cells/area) of the tissue section 
were considered interpretable.
RESULTS
Case Series
The clinical, radiographic, and pathologic features of 
the eight patients identified with NMC in the institutional con-
sultative practice are detailed in Tables 1–3. Selected radio-
graphic, pathologic, and/or molecular features of cases 3, 5, 
6, 7, and 8 have been included in previous reports.1,13,15,16 The 
mean age of the patients at the time of diagnosis was 41 years 
(median 30, range 21–68). Clinical history was available for 
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TABLE 1.  Clinical Features of Patients Diagnosed with Primary Pulmonary NUT Midline Carcinoma
Case # Age Sex
Tobacco  
History Presenting Symptoms Treatment Outcome
Survival Time 
(Months) References
1 68 F Unknown Unknown Unknown Death 1 None
2 21 F Never Right flank and shoulder  
pain, cough × 1 mo
Chemotherapy Death 4 None
3 23 M 2-pack years Cough × 2 mos Chemotherapy
Extrapleural 
pneumonectomy
Death 2 Bair et al. (2014)
4 63 F Never Cough × 6 mos, right chest/ 
back/shoulder pain
Chemotherapy Death 2 None
5 37 M Never Cough × 3 mos Chemotherapy Death 1 French et al. (2014)
6 63 M Pipe smoker, 40 
yrs
Dyspnea, cough,  
hemoptysis × 2 mos
- Death 1 Bair et al. (2014)
7 26 M Never Fever, URI × 2 mos Chemotherapy Death 2 Bair et al. (2014)
8 30 M 3-pack years Shoulder pain, cough with 
hemoptysis × 1 mo
Chemotherapy Death 5 Bair et al. (2014) 
Filippakopoulos et al. 
(2010), Grayson et al. 
(2014)
9 29 F 20-pack years Cough, fever × 2 mos Chemotherapy, 
radiation
Death 3 None
TABLE 2.  Radiographic Features of Primary Pulmonary NUT Midline Carcinoma
Case # Site
Size 
(cm) Lung Pleura
Contralateral 
Lung 
Involvement Lymphadenopathy
Extrathoracic 
Sites PET
1 No images
2 RLL, central 5 × 5 Postobstructive 
atelectasis
Large effusion
Pleural nodule
None Mediastinal
Subcarinal
Hilar(R)
+ necrosis
Subcutis, bone Intensely FDG 
avid, including 
bone and 
soft tissue 
metastases
3 RLL, central 11 × 6 Postobstructive 
atelectasis
Large effusion, 
pleural nodules 
with central 
necrosis
Small left-sided 
effusion
Mediastinal
Subcarinal
Hilar(R) 
+ necrosis
None detected Intensely 
FDG avid 
with central 
photopenia
4 RUL, central 8 × 5 Postobstructive 
atelectasis, 
lymphangitic 
spread
Small effusion None Supraclavicular
Hilar
Mediastinal
Axillary (B)
(R) retrocrural 
and aorto- 
caval nodes, 
bone
Intensely FDG 
avid
5 RLL, central 7 × 4 Postobstructive 
atelectasis
Large effusion
Pleural 
thickening
Trace left effusion Supraclavicular
Hilar
Mediastinal(B)
Paraesophageal(L)
Liver, bone N/A
6 LUL, central 11 × 10 Postobstructive 
atelectasis, 
lymphangitic 
spread
Large effusion
Pleural nodules
Small right 
effusion
Supraclavicular
Mediastinal(B)
Hilar(L)
None detected N/A
7 RLL, central 9 × 8 Postobstructive 
atelectasis
Small right 
effusion
Trace left effusion Mediastinal
Subcarinal
Hilar(R)
None detected Intensely 
FDG avid 
with central 
photopenia
8 LLL, central 8 × 6 Postobstructive 
atelectasis
Moderate 
effusion
Pleural nodules
none Mediastinal(B)
Subcarinal
Hilar(L)
+ necrosis
Liver, bone N/A
9 RML 10 × 10 Postobstructive 
atelectasis
Small right 
effusion
None Hilar (B)
Mediastinal (B)
None Intensely FDG 
avid
RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; LUL, left upper lobe; LLL, left lower lobe; N/A, not available; B, bilateral; PET, positron emission 
tomography; FDG, 18F fluorodeoxyglucose.
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seven patients. Of these, six presented with a history of cough 
for one to three months preceding their diagnosis and three 
complained of shoulder and/or flank pain. One patient had a 
long standing history of pipe smoking; all others were never or 
light smokers (Table 1). All were otherwise previously healthy.
Chest CT imaging was available for review in seven 
patients (Table 2). In all cases, the primary lung mass was 
centrally located, with a predilection for the lower lobes (five 
of seven) and the right side (five of seven). The primary tumor 
consistently presented as a large mass (range 5–11 cm in lon-
gest diameter) with irregular borders and low density compo-
nents suggestive of necrosis and was confluent with ipsilateral 
hilar and mediastinal lymph nodes (Fig. 1). Ipsilateral pleural 
disease was consistently present with pleural effusion in all 
cases, with accompanying pleural masses or thickening noted 
in five cases. The contralateral lung had no evidence of dis-
ease involvement on CT in all cases, other than trace or small 
pleural effusions in four cases. Regional adenopathy was simi-
larly more pronounced on the side of the dominant mass and 
was noted in all cases; bilateral mediastinal lymphadenopathy 
was present in four cases, including three cases with bilateral 
supraclavicular nodal involvement. In four cases evaluated 
with PET/CT, all sites of tumor were intensely FDG-avid with 
SUVmax measuring as high as 10 in some cases. In two of 
the cases with PET, central photopenia was noted in the lung 
mass suggesting necrosis. Definite bone involvement was 
seen in three patients, present as multiple lytic lesions on CT 
that were FDG-avid on PET/CT. In one case with multiple 
bone metastasis on PET and CT, bone scintigraphy was nega-
tive. Other distant sites of metastasis detected by CT and/or 
PET imaging included liver, subcutaneous soft tissue, and ret-
roperitoneal lymph nodes. All cases were negative for brain 
metastases on imaging (five cases with brain MRI and two 
cases with head CT).
Pathologic features are detailed in Table 3. Six of eight 
cases arrived in consultation with another suggested diagno-
sis, including NSCLC, not otherwise specified, adenosqua-
mous carcinoma, thymic carcinoma, germ cell tumor, and 
lymphoma. Characteristic morphologic features included 
nested to sheetlike growth of a monomorphic proliferation of 
intermediate-sized round to epithelioid tumor cells with high 
nuclear:cytoplasmic ratio, open chromatin, variably promi-
nent nucleoli, and small amounts of pale, amphophilic cyto-
plasm. Two cases showed multifocal crush artifact and nuclear 
molding, features most commonly associated with small cell 
carcinomas. One case, obtained from an extrapleural pneu-
monectomy specimen performed after chemotherapy, showed 
polygonal cells with prominent cherry-red nucleoli and more 
abundant pale, eosinophilic cytoplasm, raising a differential 
diagnosis of malignant melanoma (Supplementary Figure 1, 
SDC, http://links.lww.com/JTO/A826).
One case originally classified as an adenosquamous car-
cinoma showed a population of primitive appearing cells with 
the cytomorphology described above admixed with a florid 
proliferation of columnar respiratory epithelial cells and a brisk 
polymorphonuclear infiltrate (Supplementary Figure 2A, SDC, 
TABLE 3.  Pathologic Features of Primary Pulmonary NUT Midline Carcinoma
Case #
Suggested 
Diagnosis
P63  
Expression
TTF-1  
Expression
Keratin 
Expression
Neuroendocrine Marker 
Expression
NUT  
IHC Result
FISH  
Result
1 Lymphoma Diffuse Negative MNF-116 (focal) Negative for 
synaptophysin, 
chromogranin, and 
CD56
Positive BRD4-NUT fusion
2 NUT midline 
carcinoma
Scattered cells ND Pan-K, Cam5.2 ND Positive BRD4-NUT fusion
3 Thymic carcinoma Multifocal Negative AE1/AE3(focal) ND Positive BRD4-NUT fusion
4 Poorly 
differentiated 
NSCLC
Focala Focal AE1/AE3, CK5/6, 
CK7 (focal), 
CK20 (focal)
Negative for 
synaptophysin, 
chromogranin
Positive Variant NUT 
rearrangement
5 Germ cell tumor Multifocal to 
diffuse
Focal Cam5.2, AE1/
AE3(focal)
Positive CD56 
(focal), negative 
for synaptophysin, 
chromogranin
Positive BRD4-NUT fusion
6 NUT midline 
carcinoma
Diffuse Negative CK7 (focal), 
CK20 (focal), 
CK5/6(focal)
Negative for 
synaptophysin, 
chromogranin, and 
CD56
Positive BRD3-NUT fusion
7 Adenosquamous 
carcinoma
Diffuse Negative Cam 5.2, AE1/
AE3(focal), 
CK5/6 (focal)
Negative for 
synaptophysin
Positive BRD4-NUT fusion
8 Poorly 
differentiated 
carcinoma
Diffuse Negative Cam5.2, AE1/AE3 Positive for synaptophysin 
(focal), negative for 
chromogranin
Positive BRD4-NUT fusion
9 NSCLC Scattered Focal ND ND Positive BRD4-NUT fusion
ap40 was also examined in this case and was positive.
ND, not done; NSCLC, non–small-cell lung carcinoma; Pan-K, Pan-cytokeratin; CK7, cytokeratin 7; CK20, cytokeratin 20; CK5/6, cytokeratin 5/6; TTF-1, thyroid transcription 
factor-1; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
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http://links.lww.com/JTO/A826). Immunohistochemistry 
showed that the primitive-appearing cells were diffusely p63 
and NUT positive and the associated columnar cell prolifera-
tion (favored to represent a reactive population) was TTF-1 
positive but p63 and NUT negative (Supplementary Figure 
2B, SDC, http://links.lww.com/JTO/A826, showing p63 stain-
ing in tumor cells; 2C, showing TTF-1 staining in reactive 
columnar cell proliferation; and 2D, showing nuclear pattern 
of Nut protein expression in tumor cells; all panels at 400×). 
All cases in the series showed at least scattered p63 expression, 
and all cases showed at least focal cytokeratin expression. One 
tumor (case 8) showed discreet islands of keratinization by 
CK5/6 IHC. Interestingly, two cases, including one obtained 
from a supraclavicular lymph node biopsy (case 5; Fig. 2A) 
showed focal (<10%), weak nuclear TTF-1 expression (Fig. 
2B). Neuroendocrine marker staining was performed in six 
cases and was focally positive in two (Table 3), including in 
one case with morphologic features of small cell carcinoma 
(Fig. 2C, D). MIB-1 proliferation index was 80–100% in two 
cases stained.
Screening Study
A total of 166 cases of in-house biopsies were success-
fully screened for NUT overexpression by immunohistochem-
istry. The original diagnoses are listed in Table 4. Based on 
recommendations that the diagnosis of NMC be considered 
only for nongland forming epithelioid malignancies,8 tumors 
diagnosed morphologically as adenocarcinoma were excluded 
from this study. Of this cohort, 54 were originally diagnosed 
as NSCLC. Additional immunohistochemistry using TTF-1 
and p40 was performed to further subclassify these cases 
according to IASLC criteria,17 with 31 reclassified as NSCLC, 
favor adenocarcinoma, eight reclassified as NSCLC, favor 
squamous cell carcinoma, and 15 remaining as NSCLC, not 
otherwise specified.
NUT overexpression was identified in one case (one 
of 166 or 0.6%), in an endobronchial biopsy originally diag-
nosed as NSCLC, and reclassified as NSCLC, NOS based on 
scattered p63 positivity and focal (<10%) TTF-1 expression in 
the same cell population. Although this was a limited biopsy, 
it had features resembling those seen in the case illustrated 
in Supplementary Figure 2 (SDC, http://links.lww.com/JTO/
A826), with primitive-appearing round to epithelioid cells 
adjacent to a population of proliferative columnar epithelium 
and a brisk polymorphonuclear infiltrate (Fig. 3A). NUT pro-
tein expression was confined to the primitive-appearing cells 
(Fig. 3B). A BRD4-NUT translocation was confirmed by FISH 
(Fig. 3C, D). This case was therefore reclassified as NMC. 
Notably, the patient from whom this biopsy was derived was 
a 29-year-old woman with a 20-pack year history of smoking 
FIGURE 1.  Contrast enhanced CT 
scan of the chest demonstrated a 
large, poorly defined mass in the 
right lower lobe (arrow, A), located 
centrally and confluent with right 
hilar and mediastinal adenopathy 
(arrows, B). Note right pleural effu-
sion (black asterisk, A) and obstructive 
atelectasis on the right (white asterisk, 
A). There was no evidence of involve-
ment of the left lung. Bone metasta-
sis was present, demonstrating lytic 
lesions (black arrow, C). Whole body 
image of the FDG-PET scan demon-
strated marked FDG avidity of the 
dominant lung lesion (white arrow, 
D), as well as metastatic sites includ-
ing innumerable osseous lesions and 
a subcutaneous lesion in the right 
flank (black arrow, D). Most of the 
osseous lesions were more notice-
able on PET than CT, and Tc-99m 
methylene diphosphonate bone 
scintigraphy was negative for osseous 
metastasis. CT, computed tomogra-
phy; FDG-PET, 18F fluorodeoxyglu-
cose-positron emission tomography.
Copyright © 2015 by the International Association for the Study of Lung Cancer
956 Copyright © 2015 by the International Association for the Study of Lung Cancer
Sholl et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 6, June 2015
and a 2-month history of cough and fevers. CT and PET/CT 
imaging showed a large, FDG-avid mass (10 cm in diameter) 
located in the right middle lobe with postobstructive atelec-
tasis and small right pleural effusion, and bilateral hilar and 
mediastinal lymphadenopathy. No evidence of involvement 
was noted in the left lung, and no distant metastasis was noted 
on PET or on brain MRI. She was treated as stage IIIB squa-
mous cell carcinoma (based on p63 positivity in a subsequent 
pleural biopsy) with carboplatin and taxol and radiation ther-
apy; however, she died of disease 3 months after her diagnosis.
DISCUSSION
Descriptions of primary pulmonary NMC have been lim-
ited to a few individual case reports or small case series;9–11,18 
as a result a clear clinicopathologic description of this entity 
is lacking. Our series is the largest reported to date and offers 
complete clinical, radiographic, and pathologic detail for eight 
of the nine included patients.
The median age of diagnosis for lung cancers overall is 
70 years, as compared with median of 30 years (mean of 41) 
in this cohort of NMC patients.19 Overall, two patients had sig-
nificant smoking history, but six had no or negligible tobacco 
exposure. At presentation, all patients complained of a month 
or more of cough and some had concurrent chest or shoulder 
pain. Despite the original descriptions of this entity in pedi-
atric patients,20 it is evident that older adults are not spared. 
Therefore, although NMC should always be included in the 
differential diagnosis of a malignant lung tumor presenting in 
a young person, it should also be considered in older adults, 
even those with a substantial smoking history, when the clini-
cal course appears unusually aggressive.
Despite chemo- or chemoradiotherapy, all patients were 
dead of disease within 5 months. Interestingly, the survival 
time reported for NMC in the largest published series, includ-
ing tumors arising at all sites, was 6.7 months,8 whereas in 
our series of primary pulmonary NMC, the median survival 
time was 2.2 months (66 days). Although it is possible that 
primary pulmonary NMC are intrinsically more aggressive 
than NMC arising at other sites, the shorter survival time may 
simply reflect a relatively delayed onset of clinical symptoms 
for primary lung tumors as compared, for instance, with pri-
mary head and neck tumors, another common site of NMC 
presentation.
CT imaging of primary pulmonary NMC, although 
not necessarily specific, appears to have some characteris-
tic features that are consistent across the cases in this study. 
All cases presented with a large primary lung mass (≥5 cm 
in diameter) that was confluent with hilar and mediastinal 
FIGURE 2. A, Hematoxylin and 
eosin stain (400×) of a NUT midline 
carcinoma showing (B) weak, scat-
tered nuclear positivity for TTF-1. C, 
Hematoxylin and eosin stain (200×) 
of a NUT midline carcinoma with 
crush artifact and nuclear molding 
(lower right) and (B) scattered tumor 
cells with membranous CD56 expres-
sion. TTF-1, thyroid transcription 
factor-1.
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adenopathy, often associated with postobstructive atelectasis 
and ipsilateral pleural involvement. Notably, the contralateral 
lung was essentially spared in all cases. Bones were the most 
common site of extrathoracic involvement, with three of eight 
cases with available imaging showing definite bony metasta-
ses in the form of purely lytic lesions on CT scan, which were 
more easily detected on PET due to marked FDG avidity. In 
one case with multiple bone metastasis on PET and CT, bone 
scintigraphy was negative. This observation is consistent with 
other published reports and suggests that a negative bone scan 
may not reliably exclude metastases in this entity.15,21 Eight 
patients had staging head imaging and all were negative for 
brain metastases. This is a notable observation, given that 
primary lung carcinomas have the highest incidence of brain 
metastases compared with other primary sites, with an inci-
dence of nearly 30% in stage IV disease.22,23 However, given 
that brain metastases have been observed in NMC,24 the find-
ings may be due to the fact that these patients did not live long 
enough to develop brain metastases.
The cytomorphology of NMC has been described exten-
sively in the literature, and the appearance of the tumor cells 
in primary pulmonary NMC recapitulates that reported at 
other sites.6,7,25 The histologic appearance may be readily con-
fused with other high grade malignancies; in our series, other 
proposed diagnoses included lymphoma, germ cell tumor, and 
TABLE 4.  Diagnoses of Lung Cancer Cases Screened by 
NUT Immunohistochemistry
Diagnosis Number
SQC
  Morphologic SQC 66
  NSCLC, favor SQC 8
ADC
  ADC, poorly differentiated 3
  NSCLC, favor ADC 31
  Adenosquamous carcinoma 4
Undifferentiated carcinoma
  NSCLC, not otherwise specified 15
  Poorly differentiated carcinoma 4
  Large cell carcinoma 2
Neuroendocrine carcinoma
  SCLC 25
  LCNEC 4
  Combined SCLC/LCNEC 2
  Combined SCLC/NSCLC 2
Total 166
SQC, squamous cell carcinoma; NSCLC, non–small-cell lung cancer; ADC, 
adenocarcinoma; SCLC, small-cell lung carcinoma; LCNEC, large cell neuroendocrine 
carcinoma.
FIGURE 3.  Retrospectively identi-
fied primary pulmonary NUT midline 
carcinoma. A, Hematoxylin and 
eosin-stained slide at 400× showing a 
primitive cell population surrounded 
by a proliferation of reactive respi-
ratory epithelial cells and marked 
neutrophilic infiltrate. B, NUT 
immunohistochemistry is positive in 
the primitive-appearing cells. C, Dual 
color FISH using probes flanking the 
NUT locus shows split-apart of red 
and green signals (white arrows) con-
sistent with NUT rearrangement. D, 
Dual color FISH using probes flanking 
the BRD4 locus shows split-apart of 
red and green signals (white arrows) 
consistent with BRD4 rearrange-
ment. Together with (C), the findings 
are consistent with a BRD4-NUT 
fusion. FISH, fluorescence in situ 
hybridization.
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adenosquamous carcinoma, in addition to relatively nonspe-
cific diagnoses, such as poorly differentiated carcinoma or 
NSCLC. Additional considerations may be small cell carci-
noma, in tumors with extensive crush artifact, or melanoma, 
in tumors with pronounced nucleoli, as we observed in a 
surgically resected NMC after neoadjuvant chemotherapy. 
Notably, two cases in this series showed focal CD56 and/or 
synaptophysin expression, findings that may further lead to 
a misdiagnosis of small cell carcinoma. In a recent series, 
two of eight patients diagnosed with small-cell lung carci-
noma under the age of 40 were retrospectively re-diagnosed 
with NMC based on positive NUT expression and rearrange-
ment by FISH.26 One tumor also showed subset positivity of 
CD56, highlighting the nonspecific character of neuroendo-
crine marker expression and the need to maintain a broad dif-
ferential when diagnosing high grade carcinomas in young 
patients. In contrast to reports of NMC arising in the anterior 
mediastinum,7 primary pulmonary NMC showed consistent 
keratin expression. Application of histone deacetylase inhib-
itors to NMC cells in vitro and in vivo drives them toward 
squamous differentiation.5 In keeping with the hypothesis 
that NMC represents a subtype of squamous cell carcinoma 
all cases in our series showed at least scattered positivity for 
p63. From a diagnostic standpoint, it is important to note that 
three of the nine cases also had focal TTF-1 expression. TTF-1 
with focal or multifocal p63 coexpression is not uncommon 
in lung tumors and favors the diagnosis of adenocarcinoma.27 
However, extensive p63/p40 expression with focal TTF-1 in 
the same tumor cell population is highly unusual among lung 
carcinomas and should bring NMC into consideration. The 
significance of TTF-1 expression in this tumor type is unclear; 
it may hint at the origin of primary pulmonary NMC from 
a pluripotent respiratory epithelial cell. Alternatively, it may 
simply represent aberrant TTF-1 expression similar to that 
reported in extrapulmonary small cell carcinomas.28
Given its rarity and likely underdiagnosis, the prevalence 
of NMC among patients with lung cancer is unknown. Based 
on the data from Haruki et al.10, one may conclude that this 
number is likely less than 1%. Using a highly specific IHC-
based screen of a cohort of consecutive diagnostic biopsies 
obtained at BWH, we retrospectively identified one primary 
pulmonary NMC among 166 tested cases of lung carcinoma 
lacking morphologic features of adenocarcinoma. This one 
case, from 2008, was diagnosed first as a NSCLC and on a 
subsequent biopsy as squamous cell carcinoma, based on p63 
expression. Therefore, in this institutional series, primary pul-
monary NMC similarly occurs in less than 1% of tumors that 
may be considered in the morphologic differential diagnosis.
In conclusion, we demonstrate that primary pulmonary 
NMC, although rare, has characteristic diagnostic features. 
In this case series, the stereotypical patient was otherwise 
healthy, typically with minimal smoking history, had a large 
burden of unilateral disease involving lung, pleura, and medi-
astinal lymph nodes, and a primitive tumor cell population 
showing keratin and p63 or p40 expression on biopsy. Tumors 
with these clinicopathologic and radiographic features should 
undergo screening with either NUT IHC and/or FISH. NMC 
of the lung is uniformly and rapidly lethal and thus prompt 
recognition is necessary to permit proper patient counseling 
and hopefully to eventually offer effective targeted therapy.
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